RPG Active Pharma to strengthen API business with Rs 243-cr investmentIllustrative image – not actual.

RPG Life Sciences has announced the execution of a business transfer agreement to transfer its active pharmaceutical ingredients (API) business to its wholly-owned subsidiary, RPG Active Pharma, on a going concern basis.

The strategic move aims to create a focused API platform with dedicated capital, enhanced management attention, and greater operational flexibility while allowing RPG Life Sciences to continue expanding its formulations business. The company has also entered into an investment agreement with healthcare-focused private equity investor InvAscent to strengthen RPG Active Pharma. Funds managed by InvAscent will make an initial investment of up to Rs 243 crore, with the overall agreement providing for investments of up to Rs 700 crore by RPG Life Sciences and InvAscent in multiple tranches. The investment will support expansion of manufacturing infrastructure, product portfolio development, process capabilities, and organic and inorganic growth opportunities. Additionally, RPG Active Pharma has signed a share purchase agreement to acquire 100 percent equity share capital of Actis Generics, an API manufacturing company based in Visakhapatnam.

The acquisition is expected to expand manufacturing capacity, strengthen operational capabilities, and enhance RPG Active Pharma’s position in the growing global API market.

← All latest storiesBack to top →